Predictive biomarkers and effectiveness of MUC1-targeted dendritic-cell-based vaccine in patients with refractory non-small cell lung cancer | Zendy

Koji Teramoto | Zendy; Yoshitomo Ozaki | Zendy; Jun Hanaoka | Zendy; Satoru Sawai | Zendy; Noriaki Tezuka | Zendy; Shozo Fujino | Zendy; Yataro Daigo | Zendy; Keiichi Kontani | Zendy

Open Access

Predictive biomarkers and effectiveness of MUC1-targeted dendritic-cell-based vaccine in patients with refractory non-small cell lung cancer

Author(s) -

Koji Teramoto,

Yoshitomo Ozaki,

Jun Hanaoka,

Satoru Sawai,

Noriaki Tezuka,

Shozo Fujino,

Yataro Daigo,

Keiichi Kontani

Publication year - 2016

Publication title -

therapeutic advances in medical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.272

H-Index - 49

eISSN - 1758-8359

pISSN - 1758-8340

DOI - 10.1177/1758834016678375

Subject(s) - medicine , adverse effect , tolerability , immunotherapy , immune system , vaccination , lung cancer , immunology , refractory (planetary science) , oncology , gastroenterology , physics , astrobiology

The dendritic cell (DC)-based vaccine targeting the highly immunogenic tumor antigen, MUC1, has been promising for a cancer immunotherapy; however, predictive biomarkers for beneficial clinical responses of the vaccine remain to be determined.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Our institutional solutions Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Discover

Explore

Home ZAIA Blog